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Abstract
All isocitrate dehydrogenase (IDH) mutant solid neoplasms exhibit highly elevated levels of D-2-hydroxyglutarate (D-2HG).
Detection of 2HG in tumor tissues currently is performed by gas or liquid chromatography-mass spectrometry (GC- or
LC-MS) or biochemical detection. While these methods are highly accurate, a considerable amount of time for tissue
preparation and a relatively high amount of tissue is required for testing. We here present a rapid approach to detect
2HG in brain tumor tissue based on matrix-assisted laser desorption ionization - time of flight mass spectrometry (MALDI-
TOF). We analyzed 26 brain tumor samples with known IDH1 or IDH2 mutation and compared readouts to those from 28
brain tumor samples of wildtype IDH status. IDH mutant samples exhibited a clear positive signal for 2HG which was not
observed in any of the IDH wildtype tumors. Our analytical pipeline allowed for 2HG detection in less than 5 min. Data
were validated by determining 2HG levels in all tissues with a biochemical assay. In conclusion, we developed a protocol
for rapid detection of 2HG levels and illustrate the possibility to use MALDI-TOF for the detection of metabolites on frozen
tissue sections in a diagnostic setting.
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Introduction
Mutations of the isocitrate dehydrogenase genes (IDH1 and
IDH2) have been detected in several tumor types including
chondrosarcoma, acute myeloid leukemia (AML), cholan-
giocarcinoma and diffuse glioma [1, 2, 5, 18, 25]. Especially
in the diagnosis of brain tumors, the IDH mutation status
has gained a dominant role for classification [16]. IDH mu-
tations are present in astrocytoma and oligodendroglioma
but absent in other glial/glioneuronal tumors entities con-
stituting differential diagnoses [21].
Mutations predominantly occur in codons 100 and 132
of IDH1 and codons 140 and 172 of IDH2. All these muta-
tions result in a change of substrate specificity. While
wildtype IDH decarboxylates isocitrate to α-ketoglutarate
(αKG), mutant IDH1 and IDH2 reduce αKG to D-2-
hydroxyglutarate (D-2HG). This results in a dramatic in-
crease of D-2HG up to 1000-fold in tumor cells carrying
an IDH mutation. Therefore, increased levels of D-2HG in
tumors can serve as a surrogate marker for mutations
either in IDH1 or in IDH2 [9]. D-2HG is considered to be
an “oncometabolite”, because it is capable to inhibit αKG-
dependent enzymes which are important for diverse
cellular processes, mainly epigenetic control.
Detection of 2HG in tissues so far has been performed
either by LC-MS or by a biochemical assay [3, 9]. While
LC-MS has the potential to detect many metabolites in a
single sample, the biochemical detection method is
restricted to detecting D-2HG only. However, it allows
parallel analyses of a large number of samples. The sensi-
tivity of both methods is comparable, but both require
time consuming sample preparation. Detection of 2HG in
vivo has been facilitated by magnetic resonance
spectroscopy (MRS). However, a widely distributed
detection of 2HG by spectroscopy appears not to be
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imminent due to limited compatibility of MRI-sequences
with the hardware available and due to complex post-
processing.
Mass spectrometry was recently proposed as another
approach to analyze brain tumors intraoperatively.
Desorption electrospray ionization (DESI)-MS was used
for the rapid determination of brain tumor margins in
the course of surgery, based on lipid signatures [10, 19].
2HG was also used as a surrogate maker of the presence
of IDH-mutant cancer cells for tumor margins resection
using DESI-MS [19, 23].
The relatively low ionization yields for 2HG using con-
ventional matrices for matrix assisted laser desorption
ionization (MALDI) time of flight (TOF)-MS limited its
use for diagnosis compared to DESI-MS.
Herein we present an approach to detect 2HG in frozen
sections of brain tumor tissues by MALDI-TOF MS
within less than 5 min. The proposed approach is a proof
of concept study to show how MALDI-TOF MS could
support diagnostic decisions on minute preparations.
Material and methods
Material
All solvents were purchased from Thermo Fisher Scientific
(Waltham, USA). The indium thin oxide (ITO)-coated glass
slides were obtained from Bruker Daltonik (Bremen,
Germany). The MALDI matrices as well as pure metabolite
compounds were purchased from Sigma-Aldrich
(Taufkirchen, Germany). The 10 μl tips and microloader
tips were purchased from Eppendorf (Hamburg, Germany).
Tissue samples
Fresh frozen tumor tissues from 54 patients with predeter-
mined IDH status were selected from the archive of the
Department of Neuropathology, Heidelberg. Of those, 26
tumor tissues carried either an IDH1 or an IDH2 muta-
tion, whereas the other 28 tumor tissues were IDH1/2
wildtype and served as negative test tissue (Additional file 1:
Table S1). The series included 11 diffuse astrocytomas
WHO grade II (DA), 4 anaplastic astrocytomas WHO
grade III (AA), 7 oligodendroglioma (O), 3 anaplastic
oligodendrogliomas (AO), 1 pilocytic astrocytomas WHO
grade I (PA), 1 ganglioglioma WHO grade I (GG), 12 glio-
blastoma WHO grade IV (GBM), 13 schwannoma WHO
grade I, and 1 non-small cell lung cancers (NSCLC). Of
the IDH mutant DA, AA, O, AO and GBM 19 contained
an IDH1R132H, 1 an IDH1R132C, 1 an IDH1R132G, 1 an
IDH1R132S, 2 an IDH2R172K, 1 an IDH2R172S and 1 an
IDH2R172M mutation.
Cases for analysis of the IDH-status via detection of
2HG were selected according to the following criteria: 1)
knowledge of IDH-status, 2) tissue size sufficient for
repeated analyses, 3) sufficient viable tumor tissue con-
tained. For IDH wildtype samples, most tissues were
selected from different brain tumor subtypes and one
CNS tissue with reactive change. For IDH-mutant cases,
gliomas with different IDH-mutations were collected.
Examples for pre-characterization of tissues are shown
in Fig. 1a-d. All samples were analyzed in an anonymous
way. Informed consent has been provided in accordance
with the local ethics committee.
Morphological analysis and immunohistochemistry
Prior to inclusion of samples, immunohistochemical
staining for IDH1 R132H-mutant protein have been per-
formed as described previously [7].
From archived tissue, frozen sections were cut to 4 μm
with a Leica CM 3050 S cryostat (Leica Biosystems,
Nussloch, Germany) in a defined orientation. H&E
stainings from all frozen sections were analyzed micro-
scopically to ensure the presence of vital tumor cells. Vital
areas were marked on the slides for orientation in the
MALDI-TOF-assay.
Detection of rare IDH mutations by sequencing
Prior to inclusion of samples, IDH1 exon 4 encompas-
sing codon 132 and IDH2 exon 4 encompassing codon
172 have been subject to analysis by direct sequencing
using an ABI 3100 DNA analyzer (Thermo Fisher
Scientific, Waltham, USA) as previously described [13].
D-2HG detection by biochemical assay
The D-2HG assay has been described previously [3]. In
brief, three 10 μm-thick slices were dissolved in 125 μl cell
lysis buffer (150 mM NaCl, 0.1% NP-40, 50 mM Tris-HCl,
pH 8.0) and subsequently treated with a deproteinization
kit (Biovision, Mountain View, CA, USA). Supernatants
were then collected and stored at − 20 °C. The total en-
zymatic reaction volume was 100 μl. Ten milliliters of
assay solution were freshly prepared for each 96-well plate
subjected to D-2HG assay. The assay solution contained
100 mM HEPES pH 8.0, 100 μM NAD+, 5 μM resazurin
(Applichem, Darmstadt, Germany), 0.1 μg HGDH and
0.01 U/ml diaphorase (0.01 U/ml; MP Biomedical, Irvine,
USA). Immediately before use, 25 μl sample volume was
added to 75 μl of assay solution and incubated at room
temperature for 30 min in black 96-well plates (Thermo
Fisher Scientific, Waltham, USA) in the dark. Fluoromet-
ric detection was performed in triplicate with 25 μl depro-
teinized sample being analyzed in each reaction with
excitation at 540 ± 10 nm and emission of 610 ± 10 nm
(FLUOstar Omega, BMG Labtech, Offenburg, Germany).
Maleic anhydride proton sponge (MAPS) synthesis
MAPS was synthesized according to previously reported
procedures [12, 24]: A solution of 1,8-Bis(dimethylami-
no)naphthalene (1.1 ml, 12 mmol – Sigma-Aldrich) in
anhydrous THF (35 ml) was added to an orange solution
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of bromovaleric anhydride (5.0 g, 24 mmol – Sigma-
Aldrich) in anhydrous THF (20 ml) under Argon at
room temperature, immediately producing a deep red
suspension. After 1 h, the suspension was concentrated
in vacuo, redissolved in THF (60 ml) and filtered
through paper. The filtrate was concentrated to give a
purple-blackish crystalline solid (3.5 g, 95% yield).
1H NMR (400 MHz, CDCl3) δ: 7.90 (d, J = 8.5 Hz,
1H), 7.56 (d, J = 8.5 Hz, 1H), 7.40 (t, J = 8.0 Hz, 1H),
6.95 (d, J = 7.6 Hz, 1H), 6.87 (s, 1H), 6.85 (d, J = 8.1 Hz,
1H), 2.95 (s, 6H), 2.80 (s, 6H).
13C NMR (101 MHz, CDCl3) δ: 166.7, 165.4, 154.9,
151.8, 146.2, 136.3, 132.0, 128.2, 127.0, 121.6, 117.8,
116.2, 115.4, 112.5, 109.5, 43.4, 43.3.
HRMS (ESI) m/z: (M +H)+ calcd for C18H19N2O3:
311.1390; found: 311.1391.
Matrix solubilization and deposition on tissues
Four μm thick frozen sections were cut and thaw
mounted onto ITO glass slides. Each slide contained both
IDH wildtype and IDH-mutant sections. Brain tumor
sections were dried at room temperature for 1 min.
Dihydroxybenzoic acid (DHB) was dissolved in a mix-
ture of ACN/aqTFA 0.1% 7:3 at a concentration of 14 mg/
ml. 9-amino acridine (9-AA) was dissolved in a mixture of
MeOH/H2O 7:3 at a concentration of 10 mg/ml. 1,5-dia-
minonaphtalene (1,5-DAN) was dissolved in a mixture of
ACN/aqTFA 0.1% 7:3 at a concentration of 6 mg/ml.
Different solvent mixtures were tested for the
solubilization of 5 mg/ml of MAPS: ACN/aqTFA 0.1%
7:3, ACN/aqTFA 0.1% 9:1 and ACN/Chloroform 9:1.
The solutions were manually deposited on top of
the regions of interest of the tissues, using a micro-
pipette and 0.5–10 μl classical tips or microloader
tips (Eppendorf, Wesseling-Berzdorf, Germany).
2HG profiling in tissues
Detection of 2HG in tissues was performed using the Rapi-
flex MALDI-TOF mass spectrometer (Bruker Daltonik,
Bremen, Germany) which is equipped with a smartbeam
laser (Nd:YAG 355 nm) operating at 10,000 Hz. The laser
was set in MS dried droplet. MALDI analyses were oper-
ated in the reflector negative mode in order to detect the
[M-H]- species of 2HG at m/z 147. The following settings
were used: mass range analyzed: m/z 0–740, ions source 1
voltage: 19.87 kV, PIE: 2.417 kV, lens: 11.672, reflector 1:
20.835 kV, reflector 2: 1.01 kV, reflector 3: 8.58 kV, detector
gain: 3135 V, sample rate 5GS/s, analog offset: 70.1 mV, glo-
bal attenuator offset: 14%, laser intensity: 70%, movement
on samples spot: off, matrix suppression: deflector. The
calibration was made in negative mode using maleic acid
(m/z 115.01), glutaric acid (m/z 131.04), alpha ketoglutarate
(m/z 145.02), ascorbic acid (m/z 175,03) and isocitric acid
(m/z 191.03).
MALDI imaging of 1,5-DAN spots
MALDI imaging was performed using a raster step of
50 μm. 5000 shots were acquired per spot and images
dataset were constructed using flex imaging (Bruker
Daltonik, Bremen, Germany).
Statistical methods
All statistical analysis was performed with Sigma Plot
Version 13.0. The corresponding test used for the
analysis is depicted in the figure legend.
Results
Evaluation of commercially available matrices for
detection of a D-2HG solution via MALDI-TOF
We aimed to find a commercially available matrix that
allows for the ionization and desorption of 2HG. So far,
only one matrix was reported to be suitable for the
MALDI analysis of 2HG in tissues using MALDI-TOF
instrumentations. This matrix, MAPS, is however not
commercially available [12].
We tested three commercially available matrices for their
capability to detect 2HG (Additional file 2: Figure S1a). We
analyzed 0.3 μl spots containing 10 mM of D-2HG. This
concentration is the mean 2HG level found in IDH-mutant
brain tumor tissues [20, 22]. We used matrices that were
previously used for the analysis of small molecules and me-
tabolites, namely 2,5-dihydroxydenzoic acid (DHB) [11]
and 9-aminoacridine (9AA) [17]. 1,5-diaminonaphtalene
(1,5-DAN) [15], a known basic matrix was also tested as it
could be adequate for the deprotonization of the acidic
2HG.
We could reliably detect 2HG only in negative mode
at m/z 147 using all the matrices, at different intensities
(Additional file 2: Figure S1a). The intensity of 2HG
using 9-AA was weaker when compared to 1,5-DAN.
No background signal was observed from the matrices
as shown in the controls when matrices alone were
analyzed (Additional file 2: Figure S1a). Given the high
reliability of 1,5-DAN to detect 2HG, we further conti-
nued our experiments using this matrix.
Evaluation of the matrices MAPS and 1,5-DAN for
detection of 2HG in test tissues via MALDI-TOF
We evaluated the capacity of 1,5-DAN to detect 2HG
in IDH mutant brain tumor tissues, and compared it
with the non-commercially available matrix MAPS
[12]. MAPS was developed to induce the negative
ionization of 2HG in the liquid phase. We attempted
to dissolve MAPS in the same solution as 1,5-DAN
(ACN/TFA 0.1% 7:3), but the high hydrophobicity of
the matrix did not allow the use of an aqueous solu-
tion. We then tested the mixture ACN/TFA 0.1% 9:1
but the solubilization of MAPS was not improved.
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Only the mixture ACN/Chloroform 9:1, as previously
described, [12] was successful for the solubilization of
MAPS.
We selected one IDH wildtype and one IDH mutant
tissue to compare the two matrices. For this first test,
droplets of 0.3 μl were deposited onto tissues, as this
volume is easy to handle with standard tips.
Both matrices allowed us to detect 2HG in tissue.
However, we could retrieve more than 3-fold higher in-
tensities of 2HG from tissues using 1,5-DAN compared
to MAPS (Fig. 1e). For this reason, we used 1,5-DAN for
all further experiments.
MALDI imaging of 2HG with 1,5-DAN spots in test tissues
We aimed to determine where the highest signals of 2HG
could be found in 1,5-DAN spots. This knowledge would
help targeting specific crystals of 1,5-DAN for analyses.
We performed MALDI imaging of 0.3 μl 1,5-DAN
spots on the test tissues. The results taught us that the
thinnest “hairy” crystals at the center of the spots
allowed retrieving the highest signal from 2HG. The
crystals appeared white and opaque by eye and through
the camera of the MALDI-TOF instrument. The opacity
of the white hairy crystals made these appear black on
optical scans (Additional file 2: Figure S1b).
MALDI imaging of 2HG with smaller 1,5-DAN spots in test
tissues
The small size of tumor areas in some biopsies may re-
quire depositing very small 1,5 DAN spots in order to
retrieve specifically the signal from cancerous regions.
We checked if smaller spots could provide a sufficient
extraction of 2HG from the tissues while ensuring the
particular crystallization where highest intensities of
2HG can be detected. The minimum volume we could
set using micropipettes was 0.05 μl. Pipetting this vo-
lume using standard 10 μl tips was difficult and resulted
in different spot sizes. To circumvent this we used
microloader tips. We first tested the reproducibility of
the spots and observed that their size was similar
between triplicates (diameter about 1 mm against 2 mm
for 0.3 μl spots).
The small spots showed the intended thin and opaque
1,5-DAN crystals (Fig. 1f ). These could clearly be recog-
nized through the camera of the MALDI-TOF instru-
ment. MALDI imaging revealed that these crystals
allowed retrieving the highest signals of 2HG.
a
e f
b c d
Fig. 1 Pre-characterization and 2HG quantification on tissue samples. a H&E staining of IDH wildtype test tissue (CNS-tissue with reactive change),
the size bar represents 500 μm. b IDH1R132H staining of IDH wildtype tissue shows no IDH1R132H positive cell. c H&E staining of IDH mutant
test tissue (diffuse astrocytoma, WHO grade II). d IDH1R132H staining of test tissue shows IDH1R132H positive cells. e MALDI-TOF spectra showing
m/z values from 146.5 to 149.5 of IDH wildtype and IDH mutant tissues with the matrices 1,5-DAN and MAPS. Peaks at m/z 147 correspond to
2HG. f Light microscopic image and corresponding MALDI-TOF image of a representative 0.05 μl 1,5-DAN spot on IDH mutant tissue. The size bar
represents 150 μm, the intensity bar shows the color coding for MALDI-TOF intensities within the scanned region
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Analysis of 2HG with 1,5-DAN in a tissue validation set
with MALDI-TOF
To validate the MALDI-TOF method for 2HG detec-
tion on tissue, we used a collection of 26 IDH mutant
tumor samples and 28 tissue samples with wildtype
IDH status. The overall size of tumor areas in the tis-
sues allowed us to drop slightly larger matrix spots.
We applied single droplets of 0.1 μl of 1,5-DAN onto
the area of interest. Within each drop, we measured
4 different spots of 5000 laser shots, resulting in
spectra from 20,000 laser shots. We detected a dis-
tinctive higher intensity of 2HG in IDH mutant tis-
sues compared to IDH wildtype samples (Fig. 2a).
2HG was strongly increased in mutant tumors irre-
spectively of the type of the IDH1 or IDH2
mutations.
a
c
e f
b
d
Fig. 2 2HG quantification of validation set. a MALDI-TOF spectra showing m/z values from 146.75 to 148.75 of IDH wildtype and IDH mutant tis-
sue with the matrices 1,5-DAN. Peaks at m/z 147 represent 2HG. The colors of the spectra correlate with the colours shown in Additional file 1:
Table S1. b Box plots of MALDI-TOF signal intensities of IDH wildtype and IDH mutant tissue at m/z 147. Statistical analysis was performed with
Wilcoxon-Mann-Whitney-Test (p < 0.0001). Error bars represent the standard deviation. c D-2HG concentrations of the validation set measured by
the biochemical assay. d Box plots of D-2HG concentrations of IDH wildtype and IDH mutant tissue. Statistical analysis was performed with
Wilcoxon-Mann-Whitney-Test (p < 0.0001). Error bars represent the standard deviation. e Correlation plot of MALDI-TOF intensities and biochem-
ical determined D-2HG concentrations. Correlation was determined by Pearson (r = 0.862, p < 0.0001). f Normalized MALDI-TOF values of valid-
ation set. Values shown are intensities divided by the total ion count of each corresponding spectra
Longuespée et al. Acta Neuropathologica Communications  (2018) 6:21 Page 5 of 9
Quantification of D-2HG by biochemical assay and
comparison to MALDI-TOF data
To validate our MALDI-TOF analysis and compare it to
an established assay, we quantified D-2HG levels in the
tissues with our biochemical assay (Fig. 2c).
Next, we analyzed the data of both measurements in
more depth, by comparing the two groups IDH wildtype
with IDH mutant. For MALDI-TOF we analyzed the sig-
nal intensity at m/z 147 (Fig. 2b) and for the biochemical
assay we used the D-2HG concentration (Fig. 2d). Both
methods can significantly distinguish IDH wildtype from
IDH mutant tissue (Fig. 2b and d).
Although absolute quantification by MALDI-TOF is not
possible without internal labeled standard, we aimed to find a
correlation between MALDI data and the biochemical assay
(Fig. 2e). A strong positive correlation could be found be-
tween MALDI intensities of m/z 147 of each spectrum and
the quantities of 2HG defined by the biochemical assay (r =
0,862). We further tried to normalize the intensity data to
allow a reliable statement about IDH status, without the use
of an internal standard. Therefore, we divided the intensity at
147 m/z by the total ion count (TIC) (Fig. 2f). The TIC corre-
sponds to the overall signal of the compounds detected in the
tissues. The number and the intensities of the compounds in
tissues can greatly impact on the detection of a given com-
pound of interest. This effect is called ion suppression. Since
the overall signals were different between spectra of the differ-
ent samples, it may have impacted differently on the final de-
tection of 2HG. Also, MS intensities can slightly vary from an
instrument to another. Dividing the intensities of 2HG by the
TIC would give a more representative value corrected for ion
suppression effects and instrumental variations.
Analysis of these results showed that IDH wildtype
samples now could reliably be distinguished from IDH
mutant samples by at least factor 2.
Real time test on a frozen section
To test whether our MALDI-TOF assay is feasible in a
diagnostic setting, we tested the assay on a frozen section
of a glioma (Fig. 3a). The time required after receiving the
a
c
d e f
b
Fig. 3 2HG measurement in real time. a H&E of frozen section, scale bar represents 150 μm. b MALDI-TOF spectra showing m/z values from 146.8 to 148.2
of one IDH wildtype as negative control and the minute preparation tissue with the matrix 1,5-DAN. Peaks at m/z 147 correspond to 2HG. c H&E staining
of FFPE-tissue of the same case. Lower left box shows the Ki67 staining of the upper right dashed box. d IDH1R132H staining of the tissue shows
IDH1R132H positive tumor cells. e GFAP staining of the tissue shows positive tumor cells. f ATRX staining shows loss of ATRX staining in tumor cells
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frozen section to obtaining the 2HG data, was 4 min and
39 s. In this case we were able to detect high amounts of
2HG (Fig. 3b, signal intensity 111,382). The high 2HG con-
centrations could also be validated with the biochemical
assay, where this case showed a D-2HG concentration of
3.12 mM. Subsequent immunohistochemical and molecular
analysis confirmed an IDH1R132H mutation in this tumor
(Fig. 3c-f).
Discussion
Rapid analysis of molecular parameters is constantly
gaining importance for diagnostics and therapy of tu-
mors. Employing the considerable increase of 2HG in
IDH mutant brain tumors we demonstrate the feasibility
of rapid detection of metabolites in fresh frozen sections
by MALDI-TOF analysis.
The current WHO guidelines demand establishing the
IDH mutation status for precise classification of diffuse
gliomas [16]. This is routinely accomplished by immu-
nohistochemical analysis with antibody H09 detecting
the IDH1R132H mutation [7]. However, in diffuse
gliomas approximately 10% of IDH mutations evade de-
tection by immunohistochemistry. These tumors harbor
either rarer variants of IDH1R132 mutations or muta-
tions in IDH2. Thus, additional analyses are required to
identify potential mutations in diffuse glioma not bin-
ding antibody H09. Typically, this is performed by
Sanger- or by cycle sequencing of the respective regions
of the IDH1 and IDH2 genes. An alternative approach
has been opened since the discovery that all tumor
relevant mutations in IDH1 and IDH2 result in a neo-
morphic enzyme activity ultimately leading to a dramatic
increase of intracellular 2HG [9]. 2HG can be detected
by LC-MS and if elevated serve as surrogate marker for
IDH mutations. Subsequently a biochemical assay has
been developed detecting 2HG with a comparable
sensitivity [3]. Our present approach follows the same
concept of detecting elevated 2HG by MALDI-TOF
analysis as a surrogate for IDH mutations.
We analyzed 26 diffuse gliomas with established
positive IDH status and compared to 28 tumors tested
negative for IDH mutations by MALDI-TOF analysis.
All IDH mutated gliomas exhibited clearly raised signals
for 2HG while all control tissues exhibited only basal
levels (Fig. 2a). A clear cutoff level of 12,100 could be estab-
lished in our setting with all IDH mutant tumors positioned
above and all IDH wildtype tissues positioned below. The
data from MALDI-TOF analysis were validated by a bio-
chemical assay [3]. We detected full agreement of both
methods in all samples of our series (Fig. 2e). Further, the
intensities of 2HG were normalized by the TIC. Dividing
the 2HG intensity by TIC resulted in a value at least 2 times
higher in tumors with IDH mutation than in IDH wildtype
tissues (Additional file 1: Table S1). Alternatively, addition
of labeled D-2HG to the matrix as internal standard could
be used for quantification of 2HG. Nevertheless, the
current setup allowed us to significantly distinguish IDH
wildtype from IDH mutant tumors.
In contrast to previous assays, MALDI-TOF can be
performed rapidly in an intraoperative diagnostic setting.
In fact, while our series was retrospective employing
stored fresh frozen tumor tissues, one case was analyzed
during routine intraoperative tumor diagnostics. So
while one frozen section was prepared for a H&E
staining, an additional section was overlaid with the
matrix 1,5-DAN. Subsequent analysis by MALDI-TOF
demonstrated high 2HG levels compatible with the in-
traoperative diagnosis of a diffuse glioma. The prepar-
ation and MALDI-TOF analysis were completed within
five minutes. In addition, MALDI-TOF analysis requires
only very small amounts of tissue which is prepared
similarly to that used in standard minute preparations.
Spotting of multiple matrices with nano/p devices on
the same section would allow testing of different
metabolites or proteins. Employing MALDI-TOF for the
detection of 2HG during intraoperative diagnostics may
currently not be the highest priority. However, it clearly
helps to validate and specify a tumor diagnosis. More
importantly our example demonstrates that MALDI-
TOF can be employed in intraoperative diagnostics and
given to its high versatility can be used for the detection
of other metabolites or characteristic marker proteins.
Further, the investment for hardware is quite beyond
current possibilities in many diagnostic centers. How-
ever, the operating costs for an individual test are very
low making MALDI-TOF analysis an attractive tool in a
future setting with multiple tests being demanded during
intraoperative diagnostics.
A central requirement for specific MALDI-TOF
testing is the availability of a suitable MALDI matrix.
Since 2HG is an acidic and hydrophilic compound, we
aimed to find a basic matrix that could be dissolved in
polar solutions. We tested three well established ma-
trices. The comparison of these matrices proved that
1,5-DAN was the most efficient for 2HG detection from
pure solutions (Additional file 2: Figure S1a). The depos-
ition of 1,5-DAN on brain tissue has already been tested
and allowed the reproducible formation of crystals in
spots [4]. 1,5-DAN allows C-terminal fragmentation of
proteins through ion source decay (ISD) [6]. It has also
been proved to be efficient for the analysis of lipids [8, 14]
and metabolites [15]. The matrix MAPS has been
previously used for detection of 2HG [12]. While we also
detected 2HG readouts by employing MAPS, the sensitiv-
ity of 1,5-DAN was proved superior (Fig. 1e). In fact, our
test proved that the detection of 2HG in tissues was about
4-fold more efficient using 1,5-DAN compared to MAPS.
This was probably due to the fact that MAPS could be
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dissolved less efficiently in aqueous solutions, leading to a
poor extraction of 2HG. Moreover, MAPS did not form
crystals. This may probably lead to a lower desorption ef-
fect. Based on our MALDI-TOF imaging data, we hypoth-
esized that the detection of 2HG in tissues using 1,5-DAN
could depend on the size and the shape of the matrix
crystals. We observed that the highest MALDI signal for
2HG was retrieved in thin opaque crystals in the middle
of the matrix spot (Fig. 1f) that could be obtained in spots
as small as 0.05 μl. We analyzed 28 IDH wildtype and 26
IDH mutant tumors. In all the tissues where the thin
opaque crystals could be observed, we could reliably
detect 2HG and correctly classify them according to their
IDH mutation status.
While this approach based on sophisticated technology
allows the determination of relevant diagnostic parame-
ters, we want to stress that this cannot replace a skilled
neuropathologist in the diagnostic process.
In conclusion, we developed a simple and quick assay
for the MALDI MS-based detection of 2HG in IDH mu-
tant brain tumor tissues. This can serve as a surrogate
marker for all tumor relevant IDH1 and IDH2 mutations.
Our approach should alert neuropathologists to the
potential of MALDI-TOF analysis for efficient testing of
multiple markers with diagnostic relevance.
Additional files
Additional file 1: Table S1. Case information. Case number, shows the
number and color code under which the corresponding tissue can be found
in Fig. 2 a (color code only), c and f (number only). IDH status, shows if the
tissue is considered IDH wildtype or mutant. Mutant type, gives information
about the IDH1/2 mutation status. If sequence, it is either wildtype (IDH1/2
wildtype) or the corresponding mutation in IDH1 or IDH2 is depicted. m/z is
the value of measured 2HG signal in the MALDI-TOF measurment. Signal
/noise, intensity, total ion count (TIC) and intensity devided by total ion count
(I/TIC) are MALDI-TOF measurement related values used for analysis.
Concentration list the measured D-2HG concentration of the tissues in mM as
mean from three technical replicates with corresponding standard deviation
(stdev). Diameter depicts the measured diameter of the tissue sample in mm.
Diagnosis, is the diagnosis following the WHO 2017 classification guidelines
(CNS = central nervous system, GBM= glioblastoma, O = oligodendroglioma,
AO = anaplastic oligodendroglioma, DA = diffuse astrocytoma, AA = anaplastic
astrocytoma). WHO grade, WHO grading if applicable. (PDF 74 kb)
Additional file 2: Figure S1. Establishing of MALDI-TOF method. (a)
MALDI-TOF spectra showing m/z values from 146.5 to 149.5 of solvent
alone (black) and 10 mM D-2HG (red) with the matrices 9AA, 1,5-DAN
and DHB. (b) Light microscopic image and corresponding MALDI-TOF
scanned image of a 1 μl 1,5-DAN spot on IDH wildtype (lower) and IDH
mutant (upper) tissue. The size bar represents 1 mm, the intensity bar
shows the color coding for MALDI-TOF intensities within the scanned
region. (PDF 196 kb)
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